Cargando…

Estimation of minimal clinically important change of the Japanese version of EQ-5D in patients with chronic noncancer pain: a retrospective research using real-world data

BACKGROUND: Quality of life (QoL) is routinely assessed and evaluated in medical research. However, in Japan, there is a lack of solid cutoff criteria for evaluating QoL improvement in chronic noncancer pain management. The present study was conducted to identify the minimal clinically important cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshizawa, Kazutake, Kobayashi, Hisanori, Fujie, Motoko, Ogawa, Yoshimasa, Yajima, Tsutomu, Kawai, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773997/
https://www.ncbi.nlm.nih.gov/pubmed/26931101
http://dx.doi.org/10.1186/s12955-016-0438-2
_version_ 1782418836137443328
author Yoshizawa, Kazutake
Kobayashi, Hisanori
Fujie, Motoko
Ogawa, Yoshimasa
Yajima, Tsutomu
Kawai, Koji
author_facet Yoshizawa, Kazutake
Kobayashi, Hisanori
Fujie, Motoko
Ogawa, Yoshimasa
Yajima, Tsutomu
Kawai, Koji
author_sort Yoshizawa, Kazutake
collection PubMed
description BACKGROUND: Quality of life (QoL) is routinely assessed and evaluated in medical research. However, in Japan, there is a lack of solid cutoff criteria for evaluating QoL improvement in chronic noncancer pain management. The present study was conducted to identify the minimal clinically important change (MCIC) of the Japanese version of EuroQol-5D 3L(EQ-5D) utility score and numeric rating scale (NRS) with an emphasis on chronic noncancer pain. METHODS: The data source for this post hoc research was the post-marketing surveillance (PMS) data for a tramadol/acetaminophen combination tablet, which was previously conducted in real-world settings. The parameters extracted from the PMS data were sociodemographic characteristics, NRS, EQ-5D, and dichotomous physician’s global impression of treatment effectiveness (PGI). The optimal cutoff points of MCIC for EQ-5D utility and NRS scores were evaluated using receiver operating characteristics (ROC) analysis. An anchor-based approach using PGI was applied. RESULTS: Data of 710 patients with chronic noncancer pain were extracted from the PMS database. The NRS score decreased by 2.7 (standard deviation, 2.3) points, whereas the EQ-5D score increased by 0.16 (0.20) points at 4 weeks from baseline. The changes from baseline in NRS and EQ-5D were significantly correlated (r = 0.53, p < 0.001). The estimated optimal cutoff points of MCIC for EQ-5D and NRS were 0.10 and −2.0 points, respectively. The area under the curve of ROC was > 0.80 in both analyses. CONCLUSION: These results demonstrated novel cutoff criteria for the Japanese version of EQ-5D, focusing on patients with chronic noncancer pain. The obtained criteria were fairly consistent and can be confidently utilized as an evaluation tool in medical research on chronic noncancer pain in Japan, with additional functionality and usability for QoL assessment in pain management practice. TRIAL REGISTRATION: The data source of this post hoc research was a PMS study with the identifier number UMIN000015901 at umin.ac.jp, UMIN clinical trial registry (UMIN-CTR).
format Online
Article
Text
id pubmed-4773997
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47739972016-03-03 Estimation of minimal clinically important change of the Japanese version of EQ-5D in patients with chronic noncancer pain: a retrospective research using real-world data Yoshizawa, Kazutake Kobayashi, Hisanori Fujie, Motoko Ogawa, Yoshimasa Yajima, Tsutomu Kawai, Koji Health Qual Life Outcomes Research BACKGROUND: Quality of life (QoL) is routinely assessed and evaluated in medical research. However, in Japan, there is a lack of solid cutoff criteria for evaluating QoL improvement in chronic noncancer pain management. The present study was conducted to identify the minimal clinically important change (MCIC) of the Japanese version of EuroQol-5D 3L(EQ-5D) utility score and numeric rating scale (NRS) with an emphasis on chronic noncancer pain. METHODS: The data source for this post hoc research was the post-marketing surveillance (PMS) data for a tramadol/acetaminophen combination tablet, which was previously conducted in real-world settings. The parameters extracted from the PMS data were sociodemographic characteristics, NRS, EQ-5D, and dichotomous physician’s global impression of treatment effectiveness (PGI). The optimal cutoff points of MCIC for EQ-5D utility and NRS scores were evaluated using receiver operating characteristics (ROC) analysis. An anchor-based approach using PGI was applied. RESULTS: Data of 710 patients with chronic noncancer pain were extracted from the PMS database. The NRS score decreased by 2.7 (standard deviation, 2.3) points, whereas the EQ-5D score increased by 0.16 (0.20) points at 4 weeks from baseline. The changes from baseline in NRS and EQ-5D were significantly correlated (r = 0.53, p < 0.001). The estimated optimal cutoff points of MCIC for EQ-5D and NRS were 0.10 and −2.0 points, respectively. The area under the curve of ROC was > 0.80 in both analyses. CONCLUSION: These results demonstrated novel cutoff criteria for the Japanese version of EQ-5D, focusing on patients with chronic noncancer pain. The obtained criteria were fairly consistent and can be confidently utilized as an evaluation tool in medical research on chronic noncancer pain in Japan, with additional functionality and usability for QoL assessment in pain management practice. TRIAL REGISTRATION: The data source of this post hoc research was a PMS study with the identifier number UMIN000015901 at umin.ac.jp, UMIN clinical trial registry (UMIN-CTR). BioMed Central 2016-03-01 /pmc/articles/PMC4773997/ /pubmed/26931101 http://dx.doi.org/10.1186/s12955-016-0438-2 Text en © Yoshizawa et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Yoshizawa, Kazutake
Kobayashi, Hisanori
Fujie, Motoko
Ogawa, Yoshimasa
Yajima, Tsutomu
Kawai, Koji
Estimation of minimal clinically important change of the Japanese version of EQ-5D in patients with chronic noncancer pain: a retrospective research using real-world data
title Estimation of minimal clinically important change of the Japanese version of EQ-5D in patients with chronic noncancer pain: a retrospective research using real-world data
title_full Estimation of minimal clinically important change of the Japanese version of EQ-5D in patients with chronic noncancer pain: a retrospective research using real-world data
title_fullStr Estimation of minimal clinically important change of the Japanese version of EQ-5D in patients with chronic noncancer pain: a retrospective research using real-world data
title_full_unstemmed Estimation of minimal clinically important change of the Japanese version of EQ-5D in patients with chronic noncancer pain: a retrospective research using real-world data
title_short Estimation of minimal clinically important change of the Japanese version of EQ-5D in patients with chronic noncancer pain: a retrospective research using real-world data
title_sort estimation of minimal clinically important change of the japanese version of eq-5d in patients with chronic noncancer pain: a retrospective research using real-world data
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773997/
https://www.ncbi.nlm.nih.gov/pubmed/26931101
http://dx.doi.org/10.1186/s12955-016-0438-2
work_keys_str_mv AT yoshizawakazutake estimationofminimalclinicallyimportantchangeofthejapaneseversionofeq5dinpatientswithchronicnoncancerpainaretrospectiveresearchusingrealworlddata
AT kobayashihisanori estimationofminimalclinicallyimportantchangeofthejapaneseversionofeq5dinpatientswithchronicnoncancerpainaretrospectiveresearchusingrealworlddata
AT fujiemotoko estimationofminimalclinicallyimportantchangeofthejapaneseversionofeq5dinpatientswithchronicnoncancerpainaretrospectiveresearchusingrealworlddata
AT ogawayoshimasa estimationofminimalclinicallyimportantchangeofthejapaneseversionofeq5dinpatientswithchronicnoncancerpainaretrospectiveresearchusingrealworlddata
AT yajimatsutomu estimationofminimalclinicallyimportantchangeofthejapaneseversionofeq5dinpatientswithchronicnoncancerpainaretrospectiveresearchusingrealworlddata
AT kawaikoji estimationofminimalclinicallyimportantchangeofthejapaneseversionofeq5dinpatientswithchronicnoncancerpainaretrospectiveresearchusingrealworlddata